Three Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1
Authors: Christoph Stephan
Journal: Annals of Internal Medicine (2015)

Letters17 March 2015Three Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1Christoph Stephan, MDChristoph Stephan, MDFrom Goethe-University Hospital, Frankfurt, Germany.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L15-5066 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:A design characteristic in Lennox and colleagues' trial (1) allowed patients to switch the third antiretroviral compound within the ACTG (AIDS Clinical Trials Group) A5257 open-label trial; this method is distinct from that of historical randomized clinical comparisons. The aim of this protocol specification may have been to enable an antiretroviral therapy switch for patients facing nonserious adverse events, thus approaching a real-life clinical setting. A prerequisite for an unbiased observation is the free dispensing of all administered study drugs. However, a booster of ritonavir, 100 mg/d, was not provided for participants randomly assigned to a protease ...References1. Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, et al; ACTG A5257 Team. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014;161:461-71. [PMID: 25285539] doi:10.7326/M14-1084 LinkGoogle Scholar2. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al; CASTLE Study Team. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372:646-55. [PMID: 18722869] doi:10.1016/S0140-6736(08)61081-8 CrossrefMedlineGoogle Scholar3. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al; AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-106. [PMID: 18480202] doi:10.1056/NEJMoa074609 CrossrefMedlineGoogle Scholar4. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al; AIDS Clinical Trials Group Study A5202 Team. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154:445-56. [PMID: 21320923] doi:10.7326/0003-4819-154-7-201104050-00316 LinkGoogle Scholar5. Sax PE, Landovitz RJ. Selecting an initial ART regimen: lessons from ACTG 5257. Medscape. 11 April 2014. Accessed at www.medscape.com/viewarticle/823164 on 23 June 2014. Google Scholar Author, Article, and Disclosure InformationAffiliations: From Goethe-University Hospital, Frankfurt, Germany.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L14-0591. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEfficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 Jeffrey L. Lennox , Raphael J. Landovitz , Heather J. Ribaudo , Ighovwerha Ofotokun , Lumine H. Na , Catherine Godfrey , Daniel R. Kuritzkes , Manish Sagar , Todd T. Brown , Susan E. Cohn , Grace A. McComsey , Francesca Aweeka , Carl J. Fichtenbaum , Rachel M. Presti , Susan L. Koletar , David W. Haas , Kristine B. Patterson , Constance A. Benson , Bryan P. Baugh , Randi Y. Leavitt , James F. Rooney , Daniel Seekins , Judith S. Currier , and Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 Jeffrey L. Lennox , Raphael J. Landovitz , Heather J. Ribaudo , Ighovwerha Ofotokun , Lumine H. Na , Catherine Godfrey , Daniel R. Kuritzkes , Manish Sagar , Todd T. Brown , Susan E. Cohn , Grace A. McComsey , Francesca Aweeka , Carl J. Fichtenbaum , Rachel M. Presti , Susan L. Koletar , David W. Haas , Kristine B. Patterson , Constance A. Benson , Bryan P. Baugh , Randi Y. Leavitt , James F. Rooney , Daniel Seekins , Judith S. Currier , and Three Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 Giuseppe Lapadula and Andrea Gori Three Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 Jeffrey L. Lennox , Raphael J. Landovitz , and Heather J. Ribaudo Three Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 Giuseppe Lapadula and Andrea Gori Three Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 Jeffrey L. Lennox , Raphael J. Landovitz , and Heather J. Ribaudo Metrics 17 March 2015Volume 162, Issue 6Page: 460-461KeywordsAdverse eventsAntiretroviral therapyAntiretroviralsClinical trialsDisclosureDrugsHIV-1HomicideProtease inhibitorsTreatment guidelines ePublished: 17 March 2015 Issue Published: 17 March 2015 CopyrightCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...